Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube

International Journal of Gynecological Cancer

Volumn 21, Issue 1, 2011, Pages 58-65

  Griffiths, Richard Wyn ^a   Zee, Ying Kiat ^a   Evans, Saran ^a   Mitchell, Claire L ^a   Kumaran, Gireesh C ^a   Welch, Richard S ^b   Jayson, Gordon C ^c   Clamp, Andrew R ^c   Hasan, Jurjees ^a  

^a CRC Department of Medical Oncology   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cancer; Chemotherapy; Ovarian; Peritoneal; Platinum; Resistance

Indexed keywords

CA 125 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; PACLITAXEL; PLATINUM; TAMOXIFEN; TAXANE DERIVATIVE; TOPOTECAN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SIZE; CANCER STAGING; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM CANCER; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CA-125 ANTIGEN; CARCINOMA; CISPLATIN; CYTOTOXINS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; PLATINUM; POLYETHYLENE GLYCOLS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 79951502577     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182049273     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96. (Pubitemid 351521864)
2. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9:389-393.
3. Bolis G, Parazzini F, Scarfone G, et al. Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer. Gynecol Oncol. 1999;72:60-64. (Pubitemid 29045448)
4. Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26:890-896. (Pubitemid 351398081)
5. Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1-8. (Pubitemid 39286270)
6. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25:2811-2818. (Pubitemid 47123191)
7. D'Agostino G, Amant F, Berteloot P, et al. Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecol Oncol. 2003;88:266-269. (Pubitemid 36331977)
8. Markman M, Blessing J, Rubin SC, et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;101:436-440. (Pubitemid 43729968)
9. Buyse M. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials. Cancer Journal. 2009;15:421-425.
10. Bomalaski JJ. The treatment of recurrent ovarian carcinoma: balancing patient desires, therapeutic benefit, cost containment and quality of life. Curr Opin Obstet Gynecol. 1999;11:11-15. (Pubitemid 29081081)
11. Donovan KA, Greene PG, Shuster JL, et al. Treatment preferences in recurrent ovarian cancer. Gynecol Oncol. 2002;86:200-211. (Pubitemid 34953505)
12. Hoskins PJ, Le N. Identifying patients unlikely to benefit from further chemotherapy: a descriptive study of outcome at each relapse in ovarian cancer. Gynecol Oncol. 2005;97:862-869. (Pubitemid 40824658)
13. du Bois A, Burges A, Meier W, et al. Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR). Ann Oncol. 2006;17:93-96. (Pubitemid 43033846)
14. van der Burg ME, de Wit R, van Putten WL, et al. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. Br J Cancer. 2002;86:19-25. (Pubitemid 34146335)
15. Papadimitriou CA, Fountzilas G, Aravantinos G, et al. Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study. Gynecol Oncol. 2004;92:152-159. (Pubitemid 38147384)
16. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312-3322. (Pubitemid 32642183)
17. Perez-Gracia JL, Carrasco EM. Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol Oncol. 2002;84:201-209. (Pubitemid 34139799)
18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216. (Pubitemid 30099779)
19. Vergote I, Rustin GJ, Eisenhauer EA, et al. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst. 2000;92:1534-1535.
20. The International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002;360:505-515.
21. Gronlund B, Hogdall C, Hilden J, et al. Should CA-125 response criteria be preferred to Response Evaluation Criteria in Solid Tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol. 2004;22:4051-4058. (Pubitemid 41199651)